Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA™ Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P Therapeutics LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.